Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
09/2000
09/28/2000WO2000013712A3 Methods and compositions for the prevention or treatment of cancer
09/28/2000WO2000013706A9 Methods for detecting, preventing, and treating renal disorders by modulating, regulating, and inhibiting connective tissue growth factor
09/28/2000WO2000009085A3 Oral formulation containing cyclosporin
09/28/2000WO2000006086A3 Use of inhibitors of the activation of cxcr4 receptor by sdf-1 in treating rheumatoid arthritis
09/28/2000WO2000003981A3 Preparation of (s)-2-amino-6,6-dimethoxyhexanoic acid methyl ester via novel dioxolanes
09/28/2000WO2000003741A3 Methods for reducing intraocular pressure using a3-adenosine antagonists
09/28/2000WO2000000483A3 Tubulin binding compounds (cobra)
09/28/2000WO1999067417A3 Fitness assay and associated methods
09/28/2000WO1998010771A8 Prevention of ovarian cancer by administration of progestin products
09/28/2000DE19913732A1 Nikotin-TTS mit einem Zusatz von Monoterpenketonen Nicotine TTS with an addition of monoterpene ketones
09/28/2000DE19913731A1 Medizinische Zubereitung, enthaltend als Wirkstoff zumindest einen Anteil von Acetylsalicylsäure Medical preparation comprising as active ingredient at least a portion of acetylsalicylic acid
09/28/2000DE19913333A1 Use of hyperforin for treating cancer, or in topical compositions optionally together with hypericin for treating e.g. inflammatory skin disease, skin aging or bacterial skin infections
09/28/2000DE19912850A1 Lösung, insbesondere für Hämo- oder Peritonealdialyse, sowie Verfahren zu deren Herstellung Solution, in particular for hemodialysis or peritoneal dialysis, as well as processes for their preparation
09/28/2000DE19912623A1 Verfahren zur Erhöhung der Stabilität bei Lagerung und/oder Anwendung lichtempfindlicher therapeutischer Systeme oder deren Bestandteile A method for increasing the stability during storage and / or application of light-sensitive therapeutic systems or components thereof
09/28/2000DE19912477A1 Self-adhesive transdermal therapeutic system for e.g. drug or hormone delivery, comprises an active agent deposit and a connected matrix, including a paper substrate
09/28/2000DE19911626A1 Use of amines or compounds that produce ammonium ions for treating inflammation, induce production of anti-inflammatory proteins
09/28/2000CA2855415A1 Phenylalanine derivatives
09/28/2000CA2377383A1 Apoptosis related genes
09/28/2000CA2371990A1 Use of stabilised oligonucleotides for preparing a medicine with antitumour activity
09/28/2000CA2371987A1 Screening method involving mgdg synthase
09/28/2000CA2368733A1 Phenylalanine derivatives
09/28/2000CA2368416A1 Treatment of gallstones
09/28/2000CA2368229A1 50 human secreted proteins
09/28/2000CA2368210A1 50 human secreted proteins
09/28/2000CA2368187A1 Upregulation of type iii endothelial cell nitric oxide synthase by hmg-coa reductase inhibitors
09/28/2000CA2368047A1 Chemokine receptor binding heterocyclic compounds
09/28/2000CA2368041A1 Indolinone compounds as kinase inhibitors
09/28/2000CA2368026A1 Oxazole and thiazole combinatorial libraries
09/28/2000CA2368024A1 Process for preparing [s-(r*,s*)]-.beta.-[[[1-[1-oxo-3-(4-piperidinyl)propyl]-3-piperidinyl]carbonyl]amino]-3-pyridinepropanoic acid and derivatives
09/28/2000CA2368023A1 Fused pyridopyridazine inhibitors of cgmp phosphodiesterase
09/28/2000CA2368009A1 Use of non-nucleoside reverse transcriptase inhibitor (mni) for the treatment of hiv infection
09/28/2000CA2367985A1 Tetrahydropyran derivatives and their use as therapeutic agents
09/28/2000CA2367963A1 Hydroxamic and carboxylic acid derivatives
09/28/2000CA2367916A1 Methods for the preparation of biphenyl isoxazole sulfonamides
09/28/2000CA2367903A1 Novel method for producing doxazosin mesylate in a crystalline modification designated as form a
09/28/2000CA2367899A1 Triazolopyrimidinol compounds and salts thereof
09/28/2000CA2367866A1 Pyridine and pyrimidine derivatives and their use as inhibitors of cytokine mediated disease
09/28/2000CA2367861A1 Quinazolines and therapeutic use thereof
09/28/2000CA2367857A1 Thiourea and urea liquid-phase combinatorial libraries: synthesis and apoptosis induction
09/28/2000CA2367504A1 A screening method for a cysteine protease inhibitor
09/28/2000CA2367464A1 Materials and methods relating to modulation of p66 expression
09/28/2000CA2367282A1 Pharmaceutical compositions comprising metal complexes
09/28/2000CA2367268A1 Weight loss after pregnancy
09/28/2000CA2367266A1 Gel-microemulsion formulations
09/28/2000CA2367262A1 Treatment of immune diseases
09/28/2000CA2367112A1 Methods for treating neurodegenerative disorders using aspartyl protease inhibitors
09/28/2000CA2367093A1 Propofol formulation containing tris
09/28/2000CA2367045A1 Treatment of certain cancers associated with weight gain
09/28/2000CA2367041A1 Treatment to lower platelet adhesiveness
09/28/2000CA2367040A1 Pharmaceutical compositions comprising a pyrimidine derivative and cyclodextrin
09/28/2000CA2367035A1 Treatment of hiatial hernia
09/28/2000CA2367022A1 Method of treating sleep apnoea
09/28/2000CA2367021A1 Method of controlling weight gain associated with therapeutic drugs
09/28/2000CA2367015A1 Methods of treating tardive dyskinesia and other movement disorders
09/28/2000CA2367002A1 Increasing cerebral bioavailability of drugs
09/28/2000CA2366998A1 Quinazoline formulations and therapeutic use thereof
09/28/2000CA2366931A1 Muscle tissue engineering
09/28/2000CA2366926A1 Pharmaceutical compositions comprising dipeptidy peptidase iv inhibitors for the promotion of growth
09/28/2000CA2366877A1 Chemical compounds and their uses
09/28/2000CA2366859A1 Method for improving the stability of stored and/or used light-sensitive therapeutic systems or components thereof
09/28/2000CA2366845A1 Composition for medicated chewing gums, process for manufacturing the same and tablets so obtained
09/28/2000CA2366691A1 48 human secreted proteins
09/28/2000CA2366660A1 Treatment of osteoarthritis
09/28/2000CA2366652A1 Treatment of pulmonary hypertension
09/28/2000CA2366650A1 Oral low dose butyrate compositions
09/28/2000CA2366613A1 Particle based vaccine composition
09/28/2000CA2366555A1 Method for detecting predisposition to a venous thromboembolic disease
09/28/2000CA2366552A1 Method for detecting superantigen activity in a biological sample
09/28/2000CA2366267A1 49 human secreted proteins
09/28/2000CA2366080A1 Prediction of diabetes impaired wound healing by urinary nitrate assay
09/28/2000CA2365405A1 Human tumor necrosis factor receptor-like 2
09/28/2000CA2365247A1 49 human secreted proteins
09/28/2000CA2365244A1 Calanolides for inhibiting btk
09/28/2000CA2365201A1 Organic-arsenic compounds
09/28/2000CA2365115A1 Compounds for use in therapy
09/28/2000CA2365081A1 Immunomodulatory steroids, in particular the hemihydrate of 16.alpha.-bromoepiandrosterone
09/28/2000CA2364687A1 Organ arrest, protection and preservation
09/28/2000CA2364608A1 Use of vitamin c or the like for stimulating skin cell synthesis
09/28/2000CA2362700A1 Tricyclic indole-2-carboxylic acid compound used as nmda receptor antagonist
09/28/2000CA2361221A1 Novel protein which induces chondrocyte differentiation
09/28/2000CA2359568A1 The use of certain affinity nmda antagonists as antidepressants
09/27/2000EP1038967A2 Virus with modified binding moiety specific for the target cells
09/27/2000EP1038962A1 Peptidoglycan biosynthetic gene murF from Streptococcus pneumoniae
09/27/2000EP1038952A2 Processes for preparation of Marek's Disease Virus using continuous avian cell lines
09/27/2000EP1038880A2 Androstanes and pregnanes for allosteric modulation of GABA receptor
09/27/2000EP1038879A1 Drugs, foods or drinks with the use of algae-derived physiologically active substances
09/27/2000EP1038873A2 Benzo(3,4)cyclobuta(1,2-c)pyrrole derivatives as inhibitors of serotonine reuptake
09/27/2000EP1038872A1 4-Phenyl-4-heteroarylpiperdine derivatives as opioid receptor ligands
09/27/2000EP1038868A2 Sulfonamides as antiviral agents
09/27/2000EP1038864A1 Novel metalloproteinase inhibitors
09/27/2000EP1038863A2 Substituted dimeric compounds, process for their preparation and pharmaceutical compositions thereof
09/27/2000EP1038552A2 Solution, in particular a hemodialysis or peritoneal dialysis solution, and method for producing same
09/27/2000EP1038538A1 Muscle tissue engineering
09/27/2000EP1038534A2 Process for the preparation of a conjugate of pharmacologically active substances
09/27/2000EP1038533A1 Medicinal compositions for treating immunodeficiency diseases
09/27/2000EP1038531A2 A composition comprising soybean isoflavones and a method for the production thereof
09/27/2000EP1038530A2 Immunomodulator comprising DNA
09/27/2000EP1038528A1 Pentosan polysulfate containing medicament and implant for treating fibrosis
09/27/2000EP1038527A1 Process for producing granulates containing riboflavine
09/27/2000EP1038526A1 Treatment of functional disorders of the lower intestinal tract and subsequent visceral pain with moxonidine
1 ... 6238 6239 6240 6241 6242 6243 6244 6245 6246 6247 6248 6249 6250 6251 6252 6253 6254 6255 6256 6257 6258 ... 7860